Contributions of Asn2198, Met2199, and Phe2200 in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding

Deborah A. Lewis; Mary L. Pound; Thomas L. Ortel

doi:10.1055/s-0037-1613464

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2003; 89(05): 795-802
DOI: 10.1055/s-0037-1613464

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Contributions of Asn²¹⁹⁸, Met²¹⁹⁹, and Phe²²⁰⁰ in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-binding

Deborah A. Lewis

¹Department of Medicine, Division of Hematology, and the Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA

,

Mary L. Pound

¹Department of Medicine, Division of Hematology, and the Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA

,

Thomas L. Ortel

¹Department of Medicine, Division of Hematology, and the Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA

› Author Affiliations

Abstract

PDF Download

Summary

The crystal structure of the factor VIII C2 domain consists of a β-sandwich core from which β-hairpins and loops extend to form a hydrophobic surface. The hydrophobic surface includes M2199 and F2200 at the tip of the 1^st β-hairpin. To determine the individual contributions of residues N2198, M2199, and F2200 to phospholipid and von Willebrand factor (vWF) binding properties of factor VIII, we prepared mutant proteins with single alanine substitutions. We found that single mutations at N2198 and M2199 had relatively little impact on cofactor activity, or phospholipid and vWF binding. However the F2200A mutant had slightly lower cofactor activity at subsaturating phospholipid concentrations. Competitive ELISAs suggested that F2200 plays a more important role in both phospholipid-binding and vWF-binding than N2198 and M2199. All mutant proteins were still recognized by a monoclonal antibody and two factor VIII inhibitors that neutralized cofactor activity and blocked factor VIII binding to phospholipids.

Presented in part at the XVIII Congress of the International Society on Thrombosis and Haemostasis, Paris, France, 6-12 July 2001, and the 43^rd Annual Meeting of the American Society of Hematology, Orlando, Florida, 7-11 December 2001

Keywords

Factor VIII - ESH4 - inhibitor - phospholipid-binding - von Willebrand factor

PDF (296 kb)

References

References
1 Sadler JE, Davie EW.. Hemophilia A, Hemophilia B and von Willebrand’s disease. In: Stamatoyannopoulos G, Majerus PW, Perlmutter RM, Varmus H.. eds. The molecular basis of blood diseases. 3 Ed Philadelphia: W. B. Saunders; 2001: 680-718.
2 Kane WH, Davie EW.. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-55.
3 Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H.. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-6.
4 Fay PJ, Coumans J-V, Walker FJ.. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266: 2172-7.
5 Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ.. Factor VIII and von Willebrand factor. Thromb Haemost 1998; 79: 456-65.
6 Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL.. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-42.
7 Macedo-Ribeiro S, Bode W, Huber R, Quinn-Allen MA, Kim SW, Ortel TL, Bourenkov GP, Bartunik HD, Stubbs MT, Kane WH, Fuentes-Prior P.. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402: 434-9.
8 Jacquemin M, Pratt K, Spiegel C, Stoddard B, Desqueper B, Lavend’homme R, Benhida A, Gilles JG, Peerlinck K, Vermylen J, d’Oiron R, Saint-Remy J-M, Lavergne J-M.. Deletion of residue Ala2201 in the factor VIII C2 domain results in mild haemophilia A and destroys a major antigenic determinant recognized by factor VIII inhibitor antibodies. Thromb Haemost 2001; Supplement OC194 (Abstract)
9 Barrow RT, Healey JF, Jacquemin MG, Saint-Remy J-M, Lollar P.. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood 2001; 97: 169-74.
10 Gilbert GE, Kaufman RJ, Arena AA, Miao HZ, Pipe SW.. Four hydrophobic amino acids of the factor VIIIC2 domain are constituents of both the membrane-binding and von Willebrand factor-binding motifs. J Biol Chem 2002; 277: 6374-81.
11 Saenko EL, Scandella D.. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von Willebrand factor. J Biol Chem 1997; 272: 18007-14.
12 Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E.. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-9.
13 Arai M, Scandella D, Hoyer LW.. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 1978-84.
14 Nordfang O, Ezban M, Dinesen B.. Reactivity of factor VIII inhibitors in a micro ELISA for factor VIII: CAg and in solid phase immuno-isolation of VIII: CAg. Thromb Haemost 1985; 53: 346-50.
15 Lewis DA, Moore KD, Ortel TL.. Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding. Blood Coagul Fibrinolysis 2003 (In press).
16 Ortel TL, Moore KD, Ezban M, Kane WH.. Effect of heterologous factor V heavy chain sequences on the secretion of recombinant human factor VIII. Thromb Haemost 1996; 75: 36-44.
17 Lewis DA, Moore KD, Ortel TL.. Factor VIII Arg2304—>His binds to phosphatidylserine and is a functional cofactor in the factor X-ase complex. Thromb Haemost 2001; 85: 260-4.
18 Ortel TL, Quinn-Allen MA, Keller FG, Peterson JA, Larocca D, Kane WH.. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras. J Biol Chem 1994; 269: 15898-905.
19 Kane WH, Devore-Carter D, Ortel TL.. Expression and characterization of recombinant human factor V and a mutant lacking a major portion of the connecting region. Biochemistry 1990; 29: 6762-8.
20 Kim SW, Ortel TL, Quinn-Allen MA, Yoo L, Worfolk L, Zhai X, Lentz BR, Kane WH.. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. Biochemistry 1999; 38: 11448-54.
21 Gomori G.. A modification of the colorimetric phosphorus determination for use with the photoelectric colorimeter. J Lab ClinMed 1942; 27: 955-60.
22 Kim SW, Quinn-Allen MA, Camp JT, Macedo-Ribeiro S, Fuentes-Prior P, Bode W, Kane WH.. Identification of functionally important amino acid residues within the C2 domain of human factor V using alanine scanning mutagenesis. Biochemistry 2000; 39: 1951-8.
23 Vlot AJ, Koppelman SJ, Meijers JC, Dama C, Van den Berg HM, Bouma BN, Sixma JJ, Willems GM.. Kinetics of factor VIII-von Willebrand factor association. Blood 1996; 87: 1809-16.
24 Izumi T, Kim SW, Greist A, Macedo-Ribeiro S, Fuentes-Prior P, Bode W, Kane WH, Ortel TL.. Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants: identification of two antigenic epitopes involved in phospholipid binding. Thromb Haemost 2001; 85: 1048-54.